Chair(s)
Prof. Yahya Choonara, University of the Witwatersrand, South AfricaIntroduction
This session addresses key challenges and opportunities in designing 21st-century patient-centric drug delivery systems for illnesses that disproportionately affect Africa and/or other low- and middle-income countries (LMICs). A deeper understanding of the pathology of diseases and their increasing prevalence requires the development of new innovative approaches to drug delivery. Advanced drug delivery provides the opportunity to produce more patient-centric medicines (for e.g. in special patient populations such as pediatrics) with superior drug safety, efficacy and quality profile. Innovative drug delivery systems can transform the management of chronic diseases by reducing drug side-effects, improving patient compliance and shortening treatment regimens for communicable and non-communicable diseases.
This overall theme aims to explore promising and innovative medicine delivery systems to improve treatment outcomes. Insights from this session will help researchers, caregivers and industry stakeholders address the complexities of treating disease and explore new ways of changing clinical practice.
Programme
11:00 – 11:05 |
Introduction by the chair |
11:05 – 11:20 |
Short oral communication from a selected submitted abstract: |
11:20 – 11:50 | The role of nanomedicines for transforming treatment of bacterial infections Prof. Thirumala Govender, University of KwaZulu Natal, South Africa |
11:50 – 12:20 | Translation of microneedle technologies from the lab to the clinic Prof. Mark Prausnitz, Georgia Institute of Technology, USA |
12:20 – 12:30 | Q&A and closing by the chair |
Learning objectives
- To get a deep understanding of innovative medicine delivery approaches to provide more patient-centric medicines while understanding the unique challenges associated with their development in Africa and low- or middle-income countries (LMICs).
- To develop proficiency in using drug delivery tools such as nanomedicine for improving medicine bioavailability and pathogen targeting.
- To recognise the need for more cost-effective approaches to treat chronic infectious diseases that ravage LMICs and new models to address formulation challenges in specific/specialised patient populations (e.g. in pediatrics and for women reproductive health).
Take home messages
- We cannot have a “one-size-fits-all” approach when treating diseases.
- Significant advancements have been made with several new innovative medicine delivery systems reaching patients.
- More patient/population-centric approaches are required and better medicine delivery methods should be explored in parallel with drug discovery programmes.